TFS Capital’s Arcturus Therapeutics ARCT Stock Holding History

TFS Capital’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-2,920	Closed	-$43K	–	654
2016 Q4	$43K	Buy	+2,920	New	+$43.7K	0.01%	696

Other funds holding ARCT

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

TFS Capital's ARCT Position: Q1 2017 in Review

TFS Capital sold out of Arcturus Therapeutics (ARCT) in Q1 2017, closing a stake of 2,920 shares — an estimated $43K sold.

TFS Capital first reported a position in ARCT in Q4 2016 and held it in 1 quarter. The position peaked at $43K in Q4 2016. 33 funds tracked by Wall St. Rank hold ARCT as of Q1 2017.

TFS Capital reported no remaining Arcturus Therapeutics position as of Q1 2017 after selling out during the quarter.
TFS Capital sold 2,920 Arcturus Therapeutics shares in Q1 2017, an estimated $43K.
TFS Capital first reported a position in Arcturus Therapeutics in Q4 2016 and held it in 1 quarter.
TFS Capital's Arcturus Therapeutics position peaked at $43K in Q4 2016.
33 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2017.

Based on TFS Capital's 13F filing for Q1 2017, filed 5 May 2017.